Fairfield, Bush & Co’s Nektar Therapeutics NKTR Stock Holding History

Fairfield, Bush & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13	Closed	-$1K	–	336
2022 Q2	$1K	Buy	+13	New	+$820	﹤0.01%	431
2020 Q2	–	Sell	-813	Closed	-$218K	–	147
2020 Q1	$218K	Sell	813 -27	-3%	-$8.35K	0.09%	116
2019 Q4	$272K	Sell	840 -33	-4%	-$9.57K	0.1%	124
2019 Q3	$239K	Sell	873 -67	-7%	-$24.6K	0.08%	134
2019 Q2	$502K	Hold	940	–	–	0.17%	95
2019 Q1	$474K	Buy	940 +140	+18%	+$83K	0.16%	99
2018 Q4	$394K	Hold	800	–	–	0.14%	106
2018 Q3	$732K	Hold	800	–	–	0.21%	94
2018 Q2	$586K	Hold	800	–	–	0.17%	100
2018 Q1	$1.27M	Hold	800	–	–	0.37%	56
2017 Q4	$717K	Hold	800	–	–	0.2%	83
2017 Q3	$288K	Buy	+800	New	+$250K	0.09%	125

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fairfield, Bush & Co's NKTR Position: Q3 2022 in Review

Fairfield, Bush & Co sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 13 shares — an estimated $1K sold.

Fairfield, Bush & Co first reported a position in NKTR in Q3 2017 and held it in 12 quarters. The position peaked at $1.27M in Q1 2018. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

Fairfield, Bush & Co reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
Fairfield, Bush & Co sold 13 Nektar Therapeutics shares in Q3 2022, an estimated $1K.
Fairfield, Bush & Co first reported a position in Nektar Therapeutics in Q3 2017 and held it in 12 quarters.
Fairfield, Bush & Co's Nektar Therapeutics position peaked at $1.27M in Q1 2018.
230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Fairfield, Bush & Co's 13F filing for Q3 2022, filed 7 Nov 2022.